Sisram Medical Ltd (HK:1696), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, announced on Tuesday the official launch of its Titanium Prime treatment concept in Hong Kong SAR.
Integrating two flagship EBD platforms, Alma PrimeX and Soprano Titanium Special Edition, the new concept expands the range of combined aesthetic solutions available locally and accelerates Sisram's strategic shift toward an integrated, multi-technology service delivery model.
Powered by Tri-Energy Synergy technology, Titanium Prime unites laser, radiofrequency, and ultrasound modalities via the exclusive BTS2 Methodology, a layered system engineered to target varying tissue depths and deliver multidimensional anti-ageing and skin rejuvenation outcomes. It leverages the complementary technical strengths of Alma PrimeX and Soprano Titanium Special Edition to focus on multi-layered tissue care spanning the epidermis, dermis, and subcutaneous layers. This approach helps to complement the diverse aesthetic needs of patients, including skin texture, firmness, and facial contours, Sisram said.
The rollout in Hong Kong SAR is expected to serve as a benchmark for tailoring localised combined treatment strategies across key APAC markets.
Biocon launches Yesafili biosimilar in US ophthalmology market
CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring
Coiled Therapeutics doses first patient with optimised AO-252 formulation
CREATE Medicines agrees strategic research collaboration with Australia's Monash University
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
Ractigen Therapeutics closes over USD31m financing for project advancement
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
European Commission approves RINVOQ for severe alopecia areata